Your browser doesn't support javascript.
loading
PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
Okuyama, Kazuki; Strid, Tobias; Kuruvilla, Jacob; Somasundaram, Rajesh; Cristobal, Susana; Smith, Emma; Prasad, Mahadesh; Fioretos, Thoas; Lilljebjörn, Henrik; Soneji, Shamit; Lang, Stefan; Ungerbäck, Jonas; Sigvardsson, Mikael.
  • Okuyama K; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Strid T; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Kuruvilla J; Division of Molecular Hematology, Lund University, Lund, Sweden.
  • Somasundaram R; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Cristobal S; Division of Molecular Hematology, Lund University, Lund, Sweden.
  • Smith E; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Prasad M; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Fioretos T; Division of Molecular Hematology, Lund University, Lund, Sweden.
  • Lilljebjörn H; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Soneji S; Division of Clinical Genetics Lund University, Lund, Sweden.
  • Lang S; Division of Clinical Genetics Lund University, Lund, Sweden.
  • Ungerbäck J; Division of Molecular Hematology, Lund University, Lund, Sweden.
  • Sigvardsson M; Division of Clinical Genetics Lund University, Lund, Sweden.
PLoS Genet ; 15(8): e1008280, 2019 08.
Article en En | MEDLINE | ID: mdl-31381561
ABSTRACT
One of the most frequently mutated proteins in human B-lineage leukemia is the transcription factor PAX5. These mutations often result in partial rather than complete loss of function of the transcription factor. While the functional dose of PAX5 has a clear connection to human malignancy, there is limited evidence for that heterozygote loss of PAX5 have a dramatic effect on the development and function of B-cell progenitors. One possible explanation comes from the finding that PAX5 mutated B-ALL often display complex karyotypes and additional mutations. Thus, PAX5 might be one component of a larger transcription factor network targeted in B-ALL. To investigate the functional network associated with PAX5 we used BioID technology to isolate proteins associated with this transcription factor in the living cell. This identified 239 proteins out of which several could be found mutated in human B-ALL. Most prominently we identified the commonly mutated IKZF1 and RUNX1, involved in the formation of ETV6-AML1 fusion protein, among the interaction partners. ChIP- as well as PLAC-seq analysis supported the idea that these factors share a multitude of target genes in human B-ALL cells. Gene expression analysis of mouse models and primary human leukemia suggested that reduced function of PAX5 increased the ability of an oncogenic form of IKZF1 or ETV6-AML to modulate gene expression. Our data reveals that PAX5 belong to a regulatory network frequently targeted by multiple mutations in B-ALL shedding light on the molecular interplay in leukemia cells.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Regulación Leucémica de la Expresión Génica / Factor de Transcripción PAX5 / Redes Reguladoras de Genes / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Regulación Leucémica de la Expresión Génica / Factor de Transcripción PAX5 / Redes Reguladoras de Genes / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2019 Tipo del documento: Article